ROSETTA CRC-203: what one clinician is saying
pumitamig in previously untreated, unresectable or metastatic colorectal cancer · NCT07221357 ↗ · Phase 2/Phase 3 · Bristol-Myers Squibb
A physician described in the sources as serving on the ROSETTA CRC-203 steering committee sees scope for treatment change, reflecting expectations for bispecifics rather than reported benefit. They offered a referral route, but additional Latin American sites were only being discussed. Their forecast about anti-VEGF versus EGFR choices concerns future bispecific development, not evidence favoring either strategy. The statements do not assess benefit or safety or establish wider clinical agreement.
Created with AI · how we check it
- edition 1
- commentary checked Nov 16, 2026
- 7 verified statements
3 findings, and what sits behind each
01. ROSETTA in colorectal cancer: why a clinician sees potential to change care
1 of the report's 1 cited clinicians · 3 statements from 1 speaker in 3 sources · 3 passages
Limitations recorded: 2.
Draws on: Population and setting, The comparison.
02. ROSETTA access: a clinician notes an open site and discusses Latin American expansion
1 of the report's 1 cited clinicians · 3 statements from 1 speaker in 3 sources · 3 passages
Limitations recorded: 2.
Draws on: Population and setting, The comparison, Design and conduct.
Beyond the trial population
03. Anti-VEGF vs EGFR: a clinician sees a possible future rerun with bispecifics
1 of the report's 1 cited clinicians · 2 statements from 1 speaker in 1 source · 1 passage
Limitations recorded: 2.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 3
1 of the report's 1 cited clinicians
ROSETTA in colorectal cancer: why a clinician sees potential to change care
3 statements from 1 speaker in 3 sources
The one named speaker in this finding holds this view, a confirmed clinician
- 3
- statements
- 3
- passages
- 3
- sources
- 1
- speaker
What the statements areViews 3Questions and uncertainty 0Clinical experience 0Comparisons 0Restated results and context 0Statement-to-passage links (a passage can back several statements)Supporting a statement 3Giving context 0Recorded with the findingLimitations: 2
3 posts and articles
Draws on: Population and setting, The comparison.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
1 of the 3 findings and 2 of the 7 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (11)
BICR, blinded independent central review; CR, complete response; CRC, colorectal cancer; EGFR, epidermal growth factor receptor; HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; OS, overall survival; PFS, progression-free survival; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors.
The full ROSETTA CRC-203 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
By the numbers
- 10commentary sources screened
- 5sources cited by verified statements
- 1named in screened sources
- 1speaker cited in the report
- 1cited speaker with a verified identity
1 cited clinician, a speaker with a confirmed clinical role, of them 1 physician. By role and specialty:
- 1 physician, specialty not confirmed
- 7verified statements, each linked to its source
- 7of them from speakers with a confirmed clinical role
- 3findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 3 | Titles free |
| Detailed analysis | 5 sections | Paid |
| Verified statements with short source quotes and links | 7 | Paid |
| Who said each statement: the cited speakers | 1 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 1 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 1 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 11 | Free |
| Sources with links | 5 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
6 discussed · 5 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Objective Response (OR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessmentno commentary found | 0 | 0 |
| Primary endpoint: Progression Free Survival (PFS) by RECIST v1.1 per blinded independent central review (BICR)no commentary found | 0 | 0 |
| Primary endpoint: Overall Survival (OS)no commentary found | 0 | 0 |
| Secondary endpointsno commentary found | 0 | 0 |
| Population and setting | 4 | 3 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 2 | 2 |
| Safety and tolerabilityno commentary found | 0 | 0 |
| Design and conduct | 2 | 2 |
| Expected clinical impact | 3 | 3 |
| Trial access, referral and geographic expansion | 3 | 3 |
| Future bispecific treatment positioning | 2 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
7 verified statements from 5 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Posts · 7 statements · 100% | ||||
| X threads | 7 | 5 | 9 | |
| Bluesky threads | 0 | 0 | 1 | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 5 / quarter
- Screened window
- Nov 5, 2025 → Aug 31, 2026
- Cited window
- Feb 27, 2026 → May 15, 2026
- Retrieved
- Nov 16, 2026
The trial
from ClinicalTrials.gov- Title
- ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- Registry
- NCT07221357
- Study IDs
- CA266-0003 · 2025-523224-45 (EU CT Number) · U1111-1325-6505 (UTN)
- Sponsor
- Bristol-Myers Squibb
- Collaborators
- BioNTech SE
- Design
- Phase 2/Phase 3 · Interventional, randomized, parallel
- Status
- Recruiting
- Enrollment
- 990 estimated
- Registered
- 2025-10-27
- Start
- 2025-12-31 actual
- Primary completion
- 2030-02-02 estimated
- Primary endpoints
- Objective Response (OR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessment
- Progression Free Survival (PFS) by RECIST v1.1 per blinded independent central review (BICR)
- Overall Survival (OS)
- Interventions
- 5 registered
More on: Colorectal cancer, pumitamig
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 2 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 39 sources about other trials or topics are not included.
- The substantive views come from one X author, described in the sources as on the ROSETTA CRC-203 steering committee. Multiple posts and reposts do not establish independent endorsement or wider HCP agreement.
- Discussion that does not explicitly name the trial, or uses other naming variants, may be missing, limiting conclusions about the breadth of HCP opinion.
Show all 7 known gaps +Fewer −
- No exact-trial publication or full protocol was identified for this edition. The cited statements do not evaluate response, progression-free survival, overall survival, safety or detailed patient selection.
- Site-access statements describe the circumstances reported on the post dates. Proposed Latin American expansion should not be read as confirmation that additional centers opened.
How reports are built and checked: Methods.
Editions and corrections
Routine maintenance: 1 fix (tags)
None of these changed a statement, finding or source.
- Nov 18, 2026 UTCtaxonomy mapping corrected
Last checked for new commentary Nov 16, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. ROSETTA CRC-203 (NCT07221357): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 16, 2026. https://www.erudio.com/reports/rosetta-crc-203-nct07221357
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "ROSETTA CRC-203" (NCT07221357), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "rosetta-crc-203-nct07221357". If you cannot make requests, read https://www.erudio.com/reports/rosetta-crc-203-nct07221357.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT07221357", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT07221357 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/rosetta-crc-203-nct07221357.json
curl https://www.erudio.com/reports/rosetta-crc-203-nct07221357.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "rosetta-crc-203-nct07221357" })release a4d0a35a78151783e42701a39b401474e2e5fb18fa1277435dc5ed0790f8147d
Questions
How much does the ROSETTA CRC-203 report cost?
This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested.
What does the ROSETTA CRC-203 report cover?
7 statements from 5 sources (5 posts), 7 of them from 1 confirmed clinician, each linked to its source. Commentary checked Nov 16, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the ROSETTA CRC-203 report?
Its preview, yes: get_report_card({ "slug": "rosetta-crc-203-nct07221357" }) on https://mcp.erudio.com/free, with no sign-in. It cannot be ordered yet. Connect your AI client.
How current is the ROSETTA CRC-203 report?
Edition 1 (version 1.0.0), accepted Nov 16, 2026 UTC; last checked for new commentary Nov 16, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.